Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00362895 · ClinicalTrials.gov registry record · Phase 3

A Bioequivalence Study of Tobradex AF

A Phase 3 study, sponsored by Alcon Research.

Completed
Registry status
Phase 3
Development phase
995
Enrollment target

NCT00362895: Completed Phase 3 study, sponsored by Alcon Research.

NCT00362895 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 995 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00362895, a Phase 3 study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 3
Development phase
995 participants
Enrollment target

Study Summary

The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.

Interventions

  • DRUG Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension
  • DRUG Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)

Trial Details

FieldValue
Enrollment Target 995 participants
Start Date 2006-04
Est. Completion 2006-08
Phase Phase 3
Alcon Research

275 total trials

What the finished NCT00362895 record still lists

NCT00362895 is an interventional study that assigns participants to a tested intervention. The registered 995 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher).

The record links to 0 conditions, and to 2 interventions - of which Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension is the first listed.

NCT00362895 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00362895 about?

NCT00362895 is a clinical study titled "A Bioequivalence Study of Tobradex AF". The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.

What is the current status of trial NCT00362895?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 995 participants. The study started on 2006-04. Estimated completion is 2006-08.

What interventions are being tested in trial NCT00362895?

The interventions under investigation include: Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension (DRUG), Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX) (DRUG).

Who is sponsoring clinical trial NCT00362895?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00362895's enrollment target sits among peer trials

995 313th of 2000 higher than 1,688 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07005024 · 996 participants · Phase 3

    DOAC - Dosing Options in AntiCoagulation Prophylaxis

  • NCT05437575 · 994 participants · Phase 3

    Prehospital Analgesia INtervention Trial (PAIN)

  • NCT06671704 · 994 participants · NA

    GC-PRO Intervention

  • NCT05987241 · 992 participants · Phase 2

    Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00362895, the US trial registry maintained by the National Library of Medicine. NCT00362895 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.